KRAS and non-small cell lung carcinoma: In 2022, brain metastasis specific activity of adagrasib has been reported by Sabari et al. [36] Retrospectively, 374 NSCLC patients with KRAS mutations (149 with G12C mutation and 225 with non-G12C mutation) were analyzed for brain metastases.